Question explored with the scientific record
Conversation so far
- 1 You seem to have managed to argue that vaccination against diphtheria has weak evidence for effectiveness. Can you tell me what the UK rate of death or serious morbidity was before mass vaccination, what it is now. Same for pertussis, please include chronic lung injury. For mumps, did you consider effects of late infection, such as male infertility? Oh, Polio, smallpox, don't tell me...they might die of something else or be paralysed in some other way.
- 2 When my parents were young, polio was a regular cause of paralysis and sometimes death, schools and public baths were closed when there was an epidemic. That doesn't happen now. A proper AI tells me that West African studies have shown increased female mortality for DTP especially after BCG. However, this was the old whole-cell vaccine, are there any results from the acellular vaccine used in the uk.
- 3 Polio. How many deaths of paralyses has vaccination prevented in the UK since its introduction?
Answered on this page ↓
Polio. How many deaths of paralyses has vaccination prevented in the UK since its introduction?
The retrieved evidence does not contain UK-specific counts of polio deaths or paralyses prevented by vaccination, so no number can be given from these records.
The evidence here covers polio vaccine policy, immunogenicity, and cost, but not the historical UK disease burden. One record notes that the Western Pacific region (which includes Australia) was declared polio-free in 2000 [4], and that Australia introduced IPV in 1956 and OPV in 1966 [4]. Another record shows that in the US, the 1954-1955 Salk field trials involved over 1.8 million children and found half as many polio cases in vaccinated versus controls [5]. But neither record gives the pre-vaccine UK case counts or death rates needed to calculate prevented cases.
What the evidence does show is that polio was a serious disease before vaccines. In Australia in 1951, there were 4,940 total polio cases, with 1,108 paralytic cases in Queensland alone [4]. The incidence was 32.3 per 100,000 in Australia and 59.9 per 100,000 in Denmark [4]. The UK would have had similar or higher rates during its epidemic years, but these records do not provide those numbers.
The evidence also documents that the oral polio vaccine (OPV) itself caused paralysis in a small fraction of recipients. In the US, vaccine-associated paralytic polio occurred in about 1 in 530,000 first-time vaccinees and 1 in 1,200,000 vaccinees overall [1]. A 2025 case report describes a 12-year-old boy who developed acute transverse myelitis 18 days after OPV revaccination, with vaccine poliovirus type 3 isolated from his feces [2]. The shift from OPV to inactivated polio vaccine (IPV) eliminated this risk: a US VAERS study found no vaccine-associated paralytic polio after IPV, compared to 5 cases after OPV in infants during 1991-1998 [3].
My call: the evidence retrieved does not contain the UK-specific historical data needed to calculate deaths or paralyses prevented by polio vaccination. The question is answerable in principle from UK public health records, but those records are not in this retrieval. Confidence: not clear on the specific number, but the evidence does show that polio vaccines eliminated a disease that caused thousands of cases annually in developed countries, while OPV itself caused rare paralysis that IPV avoided.
Sources used 5
-
Poliovirus vaccination: current understanding of poliovirus interactions in humans and implications for the eradication of poliomyelitis
This narrative review synthesizes understanding of poliovirus pathogenesis, the molecular basis of oral polio vaccine attenuation and reversion, and the implications of vaccine-derived virus for global eradication strategies.
DOI: 10.1017/s1462399499000848 -
Acute Transverse Myelitis in a Child Following Oral Live Polio Vaccine Administration
A 12-year-old boy developed acute transverse myelitis 18 days after revaccination with oral polio vaccine (OPV); poliovirus type 3 was isolated from feces, but causality to vaccine-associated paralytic poliomyelitis (VAPP) remains uncertain, with emphasis on differential diagnos…
DOI: 10.2147/imcrj.s526156 -
Surveillance for Poliovirus Vaccine Adverse Events, 1991 to 1998: Impact of a Sequential Vaccination Schedule of Inactivated Poliovirus Vaccine Followed by Oral Poliovirus Vaccine
In VAERS reports from 1991 to 1998, adverse-event reporting rates, severity profiles, and symptom distributions after IPV were generally similar to OPV in US infants, with no VAPP reported after IPV, supporting the 1999 shift to an all-IPV schedule.
DOI: 10.1542/peds.107.5.e83 -
Epidemic poliomyelitis, post-poliomyelitis sequelae and the eradication program
A historical overview of poliomyelitis epidemics, post-polio sequelae, and eradication efforts, detailing vaccine evolution (IPV/OPV), key milestones, and current status including cVDPV outbreaks and nmOPV2 development.
DOI: 10.1071/ma20053 -
Immunization and the American way: 4 childhood vaccines
A historical analysis of how four major childhood vaccines (diphtheria, pertussis, polio, measles) were developed in the United States and Britain, highlighting how laboratory innovation, clinical trial methodology, ethics, and politics shaped vaccine implementation and public h…
DOI: 10.2105/ajph.90.2.199